MedPath
Found 4 clinical trials|View Analysis
Sort by:

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
Interventions
First Posted Date
2022-06-08
Last Posted Date
2022-06-24
Lead Sponsor
Hebei Medical University
Target Recruit Count
30
Registration Number
NCT05410847

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2
Conditions
Gastric Cancer With Positive Exfoliative Cancer Cells
Interventions
First Posted Date
2018-10-24
Last Posted Date
2018-10-31
Lead Sponsor
Hebei Medical University
Target Recruit Count
36
Registration Number
NCT03718624

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2
Conditions
Gastric Cancer
Interventions
First Posted Date
2018-02-09
Last Posted Date
2018-02-09
Lead Sponsor
Hebei Medical University
Target Recruit Count
38
Registration Number
NCT03428425

Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2
Conditions
Gastric Cancer
Interventions
First Posted Date
2015-07-29
Last Posted Date
2017-10-09
Lead Sponsor
Hebei Medical University
Target Recruit Count
48
Registration Number
NCT02510469
Locations
🇨🇳

Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

© Copyright 2025. All Rights Reserved by MedPath